HUMANIGEN INCORPORATED (OTCMKTS:HGEN) Can’t Be Less Risky. Short Interest Decreased

February 13, 2018 - By Adrian Mccoy

The stock of HUMANIGEN INCORPORATED (OTCMKTS:HGEN) registered a decrease of 58.97% in short interest. HGEN’s total short interest was 3,200 shares in February as published by FINRA. Its down 58.97% from 7,800 shares, reported previously. With 7,600 shares average volume, it will take short sellers 0 days to cover their HGEN’s short positions.

The stock increased 5.08% or $0.03 during the last trading session, reaching $0.62. About 6,000 shares traded. Humanigen, Inc. (OTCMKTS:HGEN) has 0.00% since February 13, 2017 and is . It has underperformed by 16.70% the S&P500.

Humanigen, Inc., a biopharmaceutical company, focuses on developing medicines for patients with neglected and rare diseases with focus on pediatric conditions in the United States. The company has market cap of $9.27 million. The companyÂ’s lead product candidate is benznidazole for the treatment of Chagas disease, a parasitic illness that can lead to long-term heart, intestinal, and neurological problems. It currently has negative earnings. It is also developing proprietary monoclonal antibodies, including lenzilumab, which is in Phase 1/2 clinical trial in patients with chronic myelomonocytic leukemia, and potentially for the treatment of juvenile myelomonocytic leukemia; and ifabotuzumab that has completed the Phase I dose escalation portion of a Phase I/II clinical trial in multiple hematologic malignancies.

More notable recent Humanigen, Inc. (OTCMKTS:HGEN) news were published by: Globenewswire.com which released: “Humanigen Appoints Chief Financial Officer” on August 28, 2017, also Globenewswire.com with their article: “Humanigen Announces up to $15 Million Committed Equity Financing Facility” published on August 24, 2017, Globenewswire.com published: “Humanigen CEO to Present at NobleCon14, BIO CEO Investor Conferences” on January 25, 2018. More interesting news about Humanigen, Inc. (OTCMKTS:HGEN) were released by: Seekingalpha.com and their article: “Comeback For KaloBios?” published on March 28, 2016 as well as Seekingalpha.com‘s news article titled: “KaloBios: Worth A Buy Now?” with publication date: November 19, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: